<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789581</url>
  </required_header>
  <id_info>
    <org_study_id>SCRI BRE 145</org_study_id>
    <secondary_id>TITAN</secondary_id>
    <nct_id>NCT00789581</nct_id>
  </id_info>
  <brief_title>A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer</brief_title>
  <acronym>TITAN</acronym>
  <official_title>Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SCRI Development Innovations, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, Phase III, open-label, multicenter study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized in a 1:1 ratio to receive one of two different treatment arms.
      Patients in treatment arm 1 will receive AC followed by ixabepilone. Patients in treatment
      arm 2 will receive AC followed by weekly paclitaxel.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>up to 5.25 years (63 months)</time_frame>
    <description>The percentage of participants with disease-free survival at 3 and 5 years. Disease-free survival (DFS) is measured from the time between randomization and the date of first documented disease recurrence, or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 5.25 years (63 months)</time_frame>
    <description>The percentage of participants with overall survival at 3 and 5 years are presented. Overall survival (OS) defined as the time between randomization to date of death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">614</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Doxorubicin/cyclophosphamide, ixabepilone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by ixabepilone at 40 mg/m2 given for 4 cycles of 21 days each.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxorubicin/cyclophosphamide, paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by paclitaxel at 80 mg/m2 weekly for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 60 mg/m2</description>
    <arm_group_label>Doxorubicin/cyclophosphamide, ixabepilone</arm_group_label>
    <arm_group_label>Doxorubicin/cyclophosphamide, paclitaxel</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 600 mg/m2</description>
    <arm_group_label>Doxorubicin/cyclophosphamide, ixabepilone</arm_group_label>
    <arm_group_label>Doxorubicin/cyclophosphamide, paclitaxel</arm_group_label>
    <other_name>Endoxan</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Procytox</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Cytophosphane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixabepilone (Ixempra)</intervention_name>
    <description>Ixabepilone 40 mg/m2</description>
    <arm_group_label>Doxorubicin/cyclophosphamide, ixabepilone</arm_group_label>
    <other_name>Ixempra</other_name>
    <other_name>azaepothilone B</other_name>
    <other_name>BMS-247550</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel (Taxol)</intervention_name>
    <description>Paclitaxel 80 mg/m2</description>
    <arm_group_label>Doxorubicin/cyclophosphamide, paclitaxel</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patients greater than or equal to18 years of age.

          2. Histologically confirmed invasive unilateral breast cancer (regardless of

             histology).

          3. Early-stage breast cancer, defined as:

               -  Node-positive disease: &gt;0.2-mm metastasis in at least one lymph node
                  (pN1mipN2b)OR

               -  Node-negative, with primary tumor &gt;1.0 cm (T1c-T3).

          4. Definitive loco-regional surgery must have been completed as specified

             below:

               -  Patients must have undergone either breast conservation surgery

                  (i.e., lumpectomy) or total mastectomy.

               -  Surgical margins of the resected section must be histologically free of

             invasive adenocarcinoma and ductal carcinoma in situ.

               -  Surgical margins involved with lobular carcinoma in situ (LCIS) will not

             be considered as a positive margin; therefore, such patients will be eligible for this
             study without additional resection.

               -  Patients must have completed axillary lymph node sampling for the pathologic
                  evaluation of axillary lymph nodes as specified below:

             Sentinel node biopsy and/or either lymph node sampling procedure or axillary
             dissection.

          5. Multicentric and multifocal invasive breast cancer is eligible if loco-regional
             surgery has been completed as described above.

          6. Patients with synchronous bilateral cancers are eligible only if:

               -  All cancers are of triple-negative phenotype, defined as ER-, PR-, HER2-.

               -  Eligibility based on the highest stage grouping.

          7. HER2 negative tumors. HER2 negativity must be confirmed by one of the

             following:

               -  FISH-negative (FISH ratio &lt;2.2), or

               -  IHC 0-1+, or

               -  IHC 2-3+ AND FISH-negative (FISH ratio &lt;2.2).

          8. Estrogen receptor negative (&lt;10% staining by IHC for estrogen receptor).

          9. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

         10. Patient must be &lt;= 84 days from having completed definitive primary breast surgery
             (either lumpectomy or mastectomy).

         11. MammoSite brachytherapy radiation is acceptable if it is performed

             immediately following surgery and prior to chemotherapy. It is recommended that
             chemotherapy be started no earlier than 2 weeks following the removal of the MammoSite
             balloon catheter.

         12. Adequate hematologic function, defined by:

               -  Absolute neutrophil count (ANC) &gt;1500/mm3

               -  Platelet count &gt;=100,000/mm3

               -  Hemoglobin &gt;9 g/dL

         13. Adequate liver function, defined by:

               -  AST and ALT &lt;=2.5 x the upper limit of normal (ULN)

               -  Total bilirubin &lt;=1.5 x ULN (unless the patient has grade 1 bilirubin

             elevation due to Gilbert's disease or a similar syndrome involving slow

             conjugation of bilirubin).

         14. Adequate renal function, defined by:

               -  Serum creatinine &lt;=1.5 x ULN

         15. Complete staging work-up &lt;=12 weeks prior to initiation of study treatment

             with computed tomography (CT) scans of the chest and abdomen/pelvis (abdomen/pelvis
             preferred; abdomen accepted), and either a positron emission tomography (PET) scan or
             a bone scan.

         16. Adequate cardiac function, defined by a left ventricular ejection fraction

             (LVEF) value of &gt;50% (or normal per institutional guidelines) by MUGA scan or
             echocardiogram (ECHO).

         17. Adequate recovery from recent surgery. At least 1 week must have elapsed from the time
             of a minor surgery (i.e., sentinel node biopsy, port-acath (placement); at least 3
             weeks must have elapsed from the time of a major surgery (i.e., lumpectomy, partial or
             total mastectomy, axillary lymph node dissection, breast reconstruction procedure).

         18. Patients with previous history of invasive cancers (including breast cancer)

             are eligible if definitive treatment was completed more than 5 years prior to

             initiating current study treatment, and there is no evidence of recurrent disease.

         19. Women of childbearing potential must have a negative serum or urine pregnancy test
             performed within 7 days prior to start of treatment. If a woman becomes pregnant or
             suspects she is pregnant while participating in this study, she must agree to inform
             her treating physician immediately.

         20. Patient must be accessible for treatment and follow-up.

         21. Women of childbearing potential must agree to use an acceptable method of birth
             control to avoid pregnancy for the duration of study treatment, and for 3 months
             thereafter.

         22. All patients must be able to understand the investigational nature of the

        study and give written informed consent prior to study entry.

        Exclusion Criteria:

          1. Women who are pregnant or breastfeeding.

          2. History of previous diagnosis of invasive breast cancer (unless treated &gt;5 years
             previously with no recurrence). History of previously treated ductal carcinoma in situ
             (DCIS) is acceptable.

          3. Any evidence or suspicion of metastatic disease other than ipsilateral

             axillary lymph nodes.

          4. Any tumor &gt;=T4 (cutaneous invasion, deep adherence, inflammatory breast cancer).

          5. Previous anthracycline chemotherapy.

          6. Concurrent use of CYP3A4 inhibitors from 72 hours prior to initiation of

             study treatment until the end of treatment with ixabepilone.

          7. Previous treatment for this breast cancer (including neoadjuvant

             chemotherapy).

          8. Previous cancer (with the exception of non-melanoma skin cancer or cervical carcinoma
             in situ) in the past 5 years (including invasive contralateral breast cancer).

          9. Peripheral neuropathy of &gt; grade 1 per NCI CTCAE v3.0.

         10. Cardiac disease, including: congestive heart failure (CHF) &gt; Class II per

             New York Heart Association (NYHA) classification; unstable angina (anginal symptoms at
             rest) or new-onset angina (i.e., began within the last 3 months), or myocardial
             infarction within the past 6 months; symptomatic CHF, unstable angina pectoris,
             cardiac arrhythmia, or cardiac ventricular arrhythmias requiring anti-arrhythmic
             therapy.

         11. History of hypersensitivity to CremophorEL (polyoxyethylated castor oil) or

             a drug formulated in CremophorEL such as paclitaxel.

         12. Use of any investigational agent within 30 days of administration of the first dose of
             study drug.

         13. Patients may not receive any other investigational or anti-cancer treatments while
             participating in this study.

         14. Concurrent severe, uncontrolled infection or intercurrent illness including,

             but not limited to, ongoing or active infection, or psychiatric illness/social

             situations that would limit compliance with study requirements.

         15. Mental condition that would prevent patient comprehension of the nature of, and risk
             associated with, the study.

         16. Inability to comply with study and/or follow-up procedures.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise A Yardley, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northeast Alabama Regional Medical Center</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Huntsville</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clearview Cancer Institute</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Arkansas Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilshire Oncology Medical Group</name>
      <address>
        <city>La Verne</city>
        <state>California</state>
        <zip>91750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hope Cancer and Research Institute</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Connecticut Hematology Oncology</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventura Medical Center</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Cancer Institute</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Care</name>
      <address>
        <city>Davie</city>
        <state>Florida</state>
        <zip>33328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Cancer Center</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Community Oncology Network</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Clinic Center for Cancer Care and Research</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Space Coast Medical Associates</name>
      <address>
        <city>Titusville</city>
        <state>Florida</state>
        <zip>32796</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta Oncology Associates</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates of Augusta</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia Cancer Specialists</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Hem Onc</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Illinois Hematology &amp; Oncology</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology of the North Shore</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates of SW Indiana</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Medical Group</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Centers</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Cancer Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants in Blood Disorders and Cancer</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baton Rouge General Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weinberg Cancer Institute at Franklin Square</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fallon Clinic</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Rapids Clinical Oncology Program</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Medical Oncology Clinic</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Cancer Care</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Clinic</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Clare's Hospital Oncology and Hematology</name>
      <address>
        <city>Denville</city>
        <state>New Jersey</state>
        <zip>07834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Northern NJ</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Oncology and Hematology</name>
      <address>
        <city>Vineland</city>
        <state>New Jersey</state>
        <zip>08360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Oncology Hematology Consultants</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamance Regional Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Ohio Oncology/Hematology, Inc./ The Mark H. Zangmeister Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology/Oncology Inc</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hickman Cancer Center (Flower Hospital)</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bux-Mont Oncology, Fox Chase Cancer Center</name>
      <address>
        <city>Rockledge</city>
        <state>Pennsylvania</state>
        <zip>18960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Oncology Associates, PA</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lowcountry Hematology Oncology</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Cancer Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Regional Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Hematology Oncology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Oncology Hematology Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Cancer Center</name>
      <address>
        <city>Collierville</city>
        <state>Tennessee</state>
        <zip>38017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Bend Cancer Center</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78463</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Oncology and Hematology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Cancer Institute</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan Hospital</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yardley DA, Arrowsmith ER, Daniel BR, Eakle J, Brufsky A, Drosick DR, Kudrik F, Bosserman LD, Keaton MR, Goble SA, Bubis JA, Priego VM, Pendergrass K, Manalo Y, Bury M, Gravenor DS, Rodriguez GI, Inhorn RC, Young RR, Harwin WN, Silver C, Hainsworth JD, Burris HA 3rd. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2017 Aug;164(3):649-658. doi: 10.1007/s10549-017-4285-6. Epub 2017 May 15.</citation>
    <PMID>28508185</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2008</study_first_submitted>
  <study_first_submitted_qc>November 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <results_first_submitted>November 7, 2016</results_first_submitted>
  <results_first_submitted_qc>March 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2017</results_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Adjuvant</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Ixabepilone</keyword>
  <keyword>TITAN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Epothilones</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was designed to evaluate if doxorubicin+cyclophosphamide (AC) followed by ixabepilone was more effective than AC followed by standard weekly paclitaxel as adjuvant treatment for patients with operable triple negative breast cancer (TNBC). Between Dec 2008 and Jan 2011, 614 women with early-stage TNBC were enrolled from 63 U.S. sites.</recruitment_details>
      <pre_assignment_details>Subjects were randomized in a 1:1 ratio to either of 2 arms: 306 to AC/Ixabepilone (Ixa); 308 to AC/paclitaxel (Pac). 489 patients completed all planned treatment with AC/Ixa or AC/Pac.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AC/Ixabepilone</title>
          <description>Doxorubicin+cyclophosphamide (AC) every 3 weeks for 4 cycles (12 weeks), followed by ixabepilone every 3 weeks for 4 cycles (12 weeks).
Doxorubicin: 60 mg/m2 Cyclophosphamide: 600 mg/m2 Ixabepilone (Ixempra): 40 mg/m2</description>
        </group>
        <group group_id="P2">
          <title>AC/Paclitaxel</title>
          <description>Doxorubicin+cyclophosphamide (AC) every 3 weeks for 4 cycles (12 weeks), followed by weekly paclitaxel for 12 weeks.
Doxorubicin: 60 mg/m2 Cyclophosphamide: 600 mg/m2 Paclitaxel (Taxol): 80 mg/m2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>AC Therapy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="306"/>
                <participants group_id="P2" count="308"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="295"/>
                <participants group_id="P2" count="291"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease recurrence</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intercurrent Illness</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Never Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Adjuvant Therapy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="295"/>
                <participants group_id="P2" count="291"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="255"/>
                <participants group_id="P2" count="234"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Never treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease recurrence</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intercurrent Illness</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analyses of baseline characteristics, demographics and efficacy includes all randomized patients.</population>
      <group_list>
        <group group_id="B1">
          <title>Ixabepilone</title>
          <description>Doxorubicin and cyclophosphamide (AC) given every 3 weeks for 4 cycles, followed by ixabepilone every 3 weeks for 4 cycles.
Doxorubicin: 60 mg/m2
Cyclophosphamide: 600 mg/m2
Ixabepilone (Ixempra): 40 mg/m2</description>
        </group>
        <group group_id="B2">
          <title>Paclitaxel</title>
          <description>Doxorubicin and cyclophosphamide (AC) given every 3 weeks for 4 cycles, followed by paclitaxel weekly for 12 weeks.
Doxorubicin: 60 mg/m2
Cyclophosphamide: 600 mg/m2
Paclitaxel (Taxol): 80 mg/m2</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="306"/>
            <count group_id="B2" value="308"/>
            <count group_id="B3" value="614"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="306"/>
                    <measurement group_id="B2" value="308"/>
                    <measurement group_id="B3" value="614"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="237"/>
                    <measurement group_id="B2" value="251"/>
                    <measurement group_id="B3" value="488"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Premenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival</title>
        <description>The percentage of participants with disease-free survival at 3 and 5 years. Disease-free survival (DFS) is measured from the time between randomization and the date of first documented disease recurrence, or death from any cause.</description>
        <time_frame>up to 5.25 years (63 months)</time_frame>
        <population>The intent-to-treat population (all randomized patients) are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>Doxorubicin and cyclophosphamide (AC) given every 3 weeks for 4 cycles, followed by ixabepilone every 3 weeks for 4 cycles.
Doxorubicin: 60 mg/m2
Cyclophosphamide: 600 mg/m2
Ixabepilone (Ixempra): 40 mg/m2</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>Doxorubicin and cyclophosphamide (AC) given every 3 weeks for 4 cycles, followed by paclitaxel given weekly for 12 weeks.
Doxorubicin: 60 mg/m2
Cyclophosphamide: 600 mg/m2
Paclitaxel (Taxol): 80 mg/m2</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <description>The percentage of participants with disease-free survival at 3 and 5 years. Disease-free survival (DFS) is measured from the time between randomization and the date of first documented disease recurrence, or death from any cause.</description>
          <population>The intent-to-treat population (all randomized patients) are included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3-year DFS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6" lower_limit="84.3" upper_limit="91.8"/>
                    <measurement group_id="O2" value="88.8" lower_limit="84.6" upper_limit="91.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-year DFS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.1" lower_limit="82.6" upper_limit="90.5"/>
                    <measurement group_id="O2" value="84.7" lower_limit="79.7" upper_limit="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The percentage of participants with overall survival at 3 and 5 years are presented. Overall survival (OS) defined as the time between randomization to date of death from any cause.</description>
        <time_frame>up to 5.25 years (63 months)</time_frame>
        <population>The intent-to-treat population (all randomized patients) are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>Doxorubicin and cyclophosphamide (AC) given every 3 weeks for 4 cycles, followed by ixabepilone every 3 weeks for 4 cycles.
Doxorubicin: 60 mg/m2
Cyclophosphamide: 600 mg/m2
Ixabepilone (Ixempra): 40 mg/m2</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>Doxorubicin and cyclophosphamide (AC) given every 3 weeks for 4 cycles, followed by paclitaxel weekly for 12 weeks.
Doxorubicin: 60 mg/m2
Cyclophosphamide: 600 mg/m2
Paclitaxel (Taxol): 80 mg/m2</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The percentage of participants with overall survival at 3 and 5 years are presented. Overall survival (OS) defined as the time between randomization to date of death from any cause.</description>
          <population>The intent-to-treat population (all randomized patients) are included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3-year OS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.4" lower_limit="86.9" upper_limit="93.7"/>
                    <measurement group_id="O2" value="93.8" lower_limit="90.2" upper_limit="96.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-year OS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7" lower_limit="85.5" upper_limit="92.7"/>
                    <measurement group_id="O2" value="89.6" lower_limit="85.0" upper_limit="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Every 3 weeks up to 28 weeks</time_frame>
      <desc>Adverse events (AEs) were collected for all patients who received at least 1 dose of treatment - from date of first treatment through the 30-day end of treatment period. All patients had at least one AE.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ixabepilone</title>
          <description>Doxorubicin and cyclophosphamide (AC) given every 3 weeks for 4 cycles, followed by ixabepilone every 3 weeks for 4 cycles.
Doxorubicin: 60 mg/m2
Cyclophosphamide: 600 mg/m2
Ixabepilone (Ixempra): 40 mg/m2</description>
        </group>
        <group group_id="E2">
          <title>Paclitaxel</title>
          <description>Doxorubicin and cyclophosphamide (AC) given every 3 weeks for 4 cycles, followed by paclitaxel given weekly for 12 weeks.
Doxorubicin: 60 mg/m2
Cyclophosphamide: 600 mg/m2
Paclitaxel (Taxol): 80 mg/m2</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>DISSEMINATED INTRAVASCULAR COAGULATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>DIASTOLIC DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>FANCONI SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>EROSIVE OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>CATHETER THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>CHEST WALL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>BREAST CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>CATHETER SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>CENTRAL LINE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>NEUTROPHIL COUNT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>HYPOPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ENDOMETRIAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>PERIPHERAL MOTOR NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>URETERIC OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BREAST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>LUNG INFILTRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>SALPINGO-OOPHORECTOMY BILATERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="305" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="304" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="227" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="221" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="250" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="251" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>weight decreased</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Neutrophil count</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Appetite decreased</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="158" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory neuropathy</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="208" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hot flush</sub_title>
                <description>All participants who had at least one dose of study drug.</description>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review/embargo results communications prior to public release for a period that is &gt;60 days but â‰¤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles H. Davis, RAC</name_or_title>
      <organization>Sarah Cannon Development Innovations</organization>
      <phone>615 524-4341</phone>
      <email>charles.davis2@scri-innovations.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

